This continuing feature updates readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number 1 killer in the United States, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, if pharmacists stay current with developments in drug therapy, they can have a significant impact on prevention and treatment.
PasternakR.C., SmithS.C.Jr, Bairey-MerzC.N., GrundyS.M., CleemanJ.I., LenfantC.; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol.2002; 40(3): 567–572.
5.
Anonymous.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet.1994; 344(8934): 1383–1389.
6.
Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial [summary for patients in Curr Cardiol Rep. 2002; 4(6): 486–487; PMID: 1237 9169]. Lancet.2002; 360(9326): 7–22.
7.
JonesP.H., DavidsonM.H., SteinE.A.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol.2003; 92(2): 152–160.
8.
GrundyS.M., CleemanJ.I., MerzC.N.; National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110(6): 763]. Circulation.2004; 110(2): 227–239.
9.
CollinsR.E., on behalf of the SEARCH Study Collaborative Group. SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine): randomized comparison of simvastatin 80 mg versus 20 mg daily for 7 years in 12,064 myocardial infarction survivors [abstract]. Circulation.2008; 118: 2310–2311.
10.
MitkaM.Researchers worry about myopathy risk for patients taking highdose simvastatin. JAMA.2009; 301(3): 261–262.
11.
de LemosJ.A., BlazingM.A., WiviottS.D.; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA.2004; 292(11): 1307–1316.
12.
GrahamD.J., StaffaJ.A., ShatinD.Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA.2004; 292(21): 2585–2590.
13.
OmarM.A., WilsonJ.P., CoxT.S.Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother.2001; 35(9): 1096–1107.
14.
RobinsonJ.G.Simvastatin: present and future perspectives. Expert Opin Pharmacother.2007; 8(13): 2159–2127.
15.
PrueksaritanontT., GorhamL.M., MaB.In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos.1997; 25(10): 1191–1199.
16.
BottorffM.B.Statin safety and drug interactions: clinical implications. Am J Cardiol.2006; 97(8A): 27C–31C.
17.
GolombB.A., CriquiM.H., WhiteH., DimsdaleJ.E.Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and bio-chemistry. Arch Intern Med.2004; 164(2): 153–162.
18.
RosensonR.S.Current overview of statin-induced myopathy. Am J Med.2004; 116(6): 408–416.
19.
OmarM.A., WilsonJ.P.FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother.2002; 36(2): 288–295.
20.
YamreudeewongW., DeBisschopM., MartinL.G., LowerD.L.Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf.2003; 26(6): 421–438.
21.
MichaletsE.L.Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy.1998; 18(1): 84–112.
22.
RicaurteB., GuirguisA., TaylorH.C., ZabriskieD.Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother.2006; 40(4): 753–757.
23.
BecquemontL., NeuvonenM., VerstuyftC.Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther.2007; 81(5): 679–684.
WratchfordP., PonteC.D.High-dose simvastatin and rhabdomyolysis. Am J Health Syst Pharm.2003; 60(7): 698–700.
26.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA.2001; 285(19): 2486–2497.
27.
ChouhanU.M., ChakrabartiS., MillwardL.J.Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother.2005; 39(10): 1760–1761.
28.
NägeleH., BehrensS., HashagenS., AziziM.Rhabdomyolysis after addition of digitoxin to chronic simvastatin and amiodarone therapy. Drug Metabol Drug Interact.2007; 22(2-3): 195–200.
29.
RotenL., SchoenenbergerR.A., KrähenbühlS., SchliengerR.G.Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother.2004; 38(6): 978–981.
30.
SalibaW.R., EliasM.Myopathy from the combination of simvastatin and amiodarone. Eur J Intern Med.2006; 17(2): 148.
31.
SchmidtG.A., HoehnsJ.D., PurcellJ.L., FriedmanR.L., ElhawiY.Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med.2007; 20(4): 411–416.
